Abstract 5800
Background
Malignant mesothelioma is an aggressive cancer with poor prognosis and few effective therapies. Due to its derivation from the mesothelium of the lung, immune cells in the tumor microenvironment (TME) may behave differently than in other solid tumors. We describe the combination of two techniques to spatially characterize the tumor-immune profile in mesothelioma.
Methods
47 FFPE mesothelioma tumors were characterized by Definiens’ Immune-Oncology Panel (IOP) and NanoString’s GeoMx™ Digital Spatial Profiling (DSP). Three alternating sequential sections were stained with IOP (CD8/PD-1/FOXP3, CD68/PD-L1/CD3, Granzyme B (GRZMB)). DSP was performed on 12 IOP-derived regions-of-interest (ROIs) on the interleaving slide by a combination of a fluorescent antibodies stain (pan-CK, CD3, CD68) and a panel of 38 UV-photocleavable DNA barcoded antibodies quantified on the nCounter® platform. Gene expression was assessed using NanoString’s PanCancer IO 360™ (IO360) assay.
Results
Cluster analysis based on the IOP revealed 6 distinct immune groups. Two of these had high IOP CD68 density, distinguished by an inhibitory phenotype (PD-L1+) and activated macrophage profile. Subsequent DSP analysis showed that e.g. VISTA, B7-H4 amongst others were higher in the active vs. inhibitory macrophage group. Overall survival (OS) was not associated with density of T cell marker expression measured by IOP/DSP. The IO360 analysis confirmed that and showed tumor-related gene signatures (e.g. proliferation, hypoxia), but not lymphoid-related ones were upregulated in patients with <12 months OS. DSP analysis of VISTA, B2M[BM1] , β-catenin and GRZMB were significantly associated with >12 months OS.
Conclusions
Based on a novel combination of two high-plex spatial analysis techniques, we propose mesothelioma subtypes where macrophages act as immune inhibitory or activated with the latter displaying a possible T-cell excluded phenotype. We also show that deep-profiling of biology within the TME identifies prognostic markers of OS. Thus, we hypothesize that this approach may guide a better understanding and help to develop effective immunotherapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bernard A. Fox.
Funding
Nanostring and Definiens.
Disclosure
T. Herz: Full / Part-time employment: Definiens. S.E. Church: Shareholder / Stockholder / Stock options, Full / Part-time employment: Nanostring. M. Widmaier: Full / Part-time employment: Definiens. A. Budco: Full / Part-time employment: Definiens. D. Medrikova: Full / Part-time employment: Definiens. I. Kanchev: Full / Part-time employment: Definiens. A. Spitzmueller: Full / Part-time employment: Definiens. A. Shaepe: Full / Part-time employment: Definiens. A. White: Shareholder / Stockholder / Stock options, Full / Part-time employment: Nanostring. J. Reeves: Shareholder / Stockholder / Stock options, Full / Part-time employment: Nanostring. A.H. Sullivan: Shareholder / Stockholder / Stock options, Full / Part-time employment: Nanostring. M. Bailey: Shareholder / Stockholder / Stock options, Full / Part-time employment: Nanostring. R. Sanborn: Advisory / Consultancy: CellDex. C. Bifulco: Advisory / Consultancy: Ventana/Roche; Advisory / Consultancy: BMS; Advisory / Consultancy: HalioDx; Advisory / Consultancy, Shareholder / Stockholder / Stock options: PrimeVax. S. Warren: Shareholder / Stockholder / Stock options, Full / Part-time employment: Nanostring. J.M. Beechem: Shareholder / Stockholder / Stock options, Full / Part-time employment: Nanostring. B. Fox: Advisory / Consultancy: Argos; Advisory / Consultancy: AstraZeneca/MedImmune; Advisory / Consultancy, Research support: Bristol-Myers Squibb; Advisory / Consultancy: Bayer; Advisory / Consultancy: CellDex; Advisory / Consultancy: Clearlight; Advisory / Consultancy, Research support: Definiens; Advisory / Consultancy, Research support: Janssen; Advisory / Consultancy, Research support: Macrogenics; Advisory / Consultancy, Research support: Nanostring; Advisory / Consultancy, Research support: OncoSec; Advisory / Consultancy, Research support: PerkinElmer/Akoya; Advisory / Consultancy, Shareholder / Stockholder / Stock options: PrimeVax; Advisory / Consultancy, Research support: Quanterix; Advisory / Consultancy, Research support: Shimadzu; Advisory / Consultancy: Ultivue; Advisory / Consultancy, Research support: Ventana/Roche; Advisory / Consultancy, Research support: Viralytics/Merck; Leadership role, Shareholder / Stockholder / Stock options: UbiVac. All other authors have declared no conflicts of interest.
Resources from the same session
3611 - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.
Presenter: Benjamin Gartrell
Session: Poster Display session 3
Resources:
Abstract
2492 - A phase 1 study of Ad5 PSA/MUC-1/Brachyury Vaccine in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Presenter: Marijo Bilusic
Session: Poster Display session 3
Resources:
Abstract
3142 - Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Presenter: Douglas McNeel
Session: Poster Display session 3
Resources:
Abstract
4327 - Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Elena Castro
Session: Poster Display session 3
Resources:
Abstract
3600 - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with Radium-223 (Ra223): Results from a prospective multicentre study
Presenter: Nuria Romero Laorden
Session: Poster Display session 3
Resources:
Abstract
3742 - Prognostic value of tumor suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
Presenter: Miguel Gonzalez Velez
Session: Poster Display session 3
Resources:
Abstract
2643 - Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial
Presenter: Sarah Benafif
Session: Poster Display session 3
Resources:
Abstract
4349 - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.
Presenter: Carlo Cattrini
Session: Poster Display session 3
Resources:
Abstract
3301 - Implications of Single Nucleotide Polymorphisms (SNPs) in Androgen Related-Genes in Outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with Abiraterone (Abi) and Enzalutamide (Enza)
Presenter: Isabel Aragon
Session: Poster Display session 3
Resources:
Abstract
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract